TheraCryf plc (TCF), a Cheshire-based biotechnology company developing medicines for addiction and neuropsychiatric disorders, has submitted an application to the Bellberry Human Research Ethics Committee in Australia for a first-in-human Phase 1 study of its lead orexin-1 (Ox-1) receptor antagonist. The submission, made on 18 November 2026, was filed on behalf of wholly owned subsidiary TheraCryf Australia Pty Ltd and aligns with the company's previously stated November 2026 timetable. The company is targeting regulatory approvals around the turn of the calendar year, which it describes as a potential major inflection point for its addiction programme.
Key Points
- TheraCryf plc (TCF) — Cheshire-based biotech focused on addiction and neuropsychiatric disorders
- Ethics application submitted to Bellberry HREC in Australia for first-in-human Ox-1 Phase 1 study
- Submission follows completion of a preclinical data package, including 28-day regulatory toxicology studies in two species, announced on 19 October 2026
- Investors should watch for HREC approval and subsequent Clinical Trial Notification lodgement with the Therapeutic Goods Administration
TheraCryf's Ox-1 Programme Targets Addiction Including Binge Eating, Alcohol and Substance Use Disorders
TheraCryf's lead asset is a novel orexin-1 receptor antagonist that the company describes as potentially best-in-class. The programme is being developed as a treatment for addiction, specifically including binge eating, alcohol use disorder, and other substance use disorders — conditions representing areas of significant unmet medical need. The company operates a capital-light, virtual development model, advancing programmes to early clinical or proof-of-concept stage before seeking partnerships with commercial pharmaceutical and biotechnology companies. This business model means the Phase 1 milestone carries particular strategic weight for future partnering discussions.
Bellberry HREC Submission Follows Completion of Two-Species Preclinical Toxicology Package
The ethics application builds directly on the preclinical data package completed and announced on 19 October 2026, which included the final reporting of 28-day regulatory toxicology studies conducted in two species. The announcement states that the submission was made exactly in line with the company's previously communicated November 2026 timetable, providing investors with confirmation that the programme has not experienced delays at this stage. Chief Executive Dr Huw Jones described the submission as "the culmination of a huge body of work" by the internal team alongside external consultants and research partners.
Australia's TGA Pathway and Clinical Trial Notification Process Are the Next Regulatory Steps
Following anticipated approval from the Bellberry HREC, TheraCryf will lodge a Clinical Trial Notification with Australia's Therapeutic Goods Administration. The announcement notes that Australia was specifically selected for its efficient and well-established pathway for early-stage clinical studies. The company continues to target the necessary approvals by the turn of the 2026 calendar year. Investors may be watching whether that timeline is maintained, as securing approval to proceed to human volunteers would, in the company's own framing, mark TheraCryf's transition to a clinical-stage neuropsychiatry company.
TheraCryf Also Advances DAT Modulator and Oncology Programmes Alongside Lead Ox-1 Asset
Beyond its lead Ox-1 programme, TheraCryf disclosed it is also developing a dopamine transporter modulator programme targeting fatigue of brain origin, including fatigue associated with multiple sclerosis, chemotherapy, and narcolepsy. The group additionally holds a legacy, grant-funded oncology programme in glioblastoma utilising SFX-01. The company is headquartered at Alderley Park, Cheshire, and its nominated adviser is Strand Hanson, with Turner Pope Investments acting as broker.



Please wait processing your request...